Daiichi Sankyo Company, Limited

Mayumi Iizuka

Kazuhiro Yoshida

Yasunori Ono

Satoshi Komoriya

Yasuhiro Nakagami

Kayoko Masuda

Emiko Hatano

Takashi Ohnuki

Yuji Kasuya

Tatsuya Inoue

Atsunobu Sakamoto

Masako Minami

Yoko Murakami

Masaru Iwasaki

The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.

Sustained-release pharmaceutical composition for treatment and prevention of eye disease

It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represented by the following formula (I): 

Terpenoid derivatives

Growing community of inventors

Edogawa-ku, Japan

Mayumi Iizuka